{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,30]],"date-time":"2025-11-30T13:52:47Z","timestamp":1764510767302,"version":"3.37.3"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,10,9]],"date-time":"2021-10-09T00:00:00Z","timestamp":1633737600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,10,9]],"date-time":"2021-10-09T00:00:00Z","timestamp":1633737600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100011488","name":"Health and Family Planning Committee of Pudong New Area","doi-asserted-by":"publisher","award":["PW2015E-1"],"award-info":[{"award-number":["PW2015E-1"]}],"id":[{"id":"10.13039\/501100011488","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81903811"],"award-info":[{"award-number":["81903811"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Cell Int"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Increasing evidence suggests that hepatitis C virus (HCV) infection is associated with non-Hodgkin\u2019s lymphoma (NHL). However, no clear consensus has been reached about the clinical features and effective treatment of HCV-associated NHL patients. We therefore performed a systematic review and meta-analysis to explore the clinical characteristics and effectiveness of antiviral treatment or rituximab administration among NHL patients with HCV infection.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Eight electronic databases, including PubMed, OVID, EMBASE, Cochrane Library, ClinicalTrials, WANFANG, CNKI, and VIP, were searched for eligible studies up to July 31, 2021. The hazard ratio (HR) or odds ratio (OR) corresponding to the 95% confidence interval (CI) was calculated to estimate the outcomes. Publication bias was assessed by Egger\u2019s and Begg\u2019s tests. Statistical analysis was performed with RevMan 5.4 software and Stata version 15.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>There were 27 shortlisted articles out of a total of 13,368 NHL patients included in the current meta-analysis. Our results demonstrated that NHL patients with HCV infection had a significantly shorter overall survival (OS: HR 1.89; 95% CI 1.42\u20132.51, P\u2009&lt;\u20090.0001) and progression-free survival (PFS: HR 1.58; 95% CI 1.26\u20131.98, P\u2009&lt;\u20090.0001), a lower overall response rate (ORR: OR 0.58, 95% CI 0.46\u20130.73, P\u2009&lt;\u20090.00001) and a higher incidence of hepatic dysfunction during chemotherapy (OR 5.96; 95% CI 2.61\u201313.62, P\u2009&lt;\u20090.0001) than NHL patients without HCV infection. HCV-positive NHL patients exhibited an advanced disease stage, an elevated level of LDH, a high-intermediate and high IPI\/FLIPI risk as well as a higher incidence of spleen and liver involvement. Moreover, antiviral treatment prolonged survival (OS: HR 0.38; 95% CI 0.24\u20130.60, P\u2009&lt;\u20090.0001), reduced disease progression [PFS\/DFS (disease-free survival): HR 0.63; 95% CI 0.46\u20130.86, P\u2009=\u20090.003] and reinforced the treatment response (ORR: OR 2.62; 95% CI 1.34\u20135.11, P\u2009=\u20090.005) among the HCV-infected NHL patients. Finally, rituximab administration was associated with a favourable OS, while liver cirrhosis and low levels of albumin predicted a poor OS for HCV-positive NHL patients.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>The current study provided compelling evidence about an inferior prognosis and distinct clinical characteristics among HCV-associated NHL patients. Antiviral treatment and rituximab-containing regimens were shown to be efficacious in improving the clinical outcomes of NHL patients with HCV infection.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12935-021-02230-1","type":"journal-article","created":{"date-parts":[[2021,10,10]],"date-time":"2021-10-10T20:26:06Z","timestamp":1633897566000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Distinct clinical features and prognostic factors of hepatitis C virus-associated non-Hodgkin\u2019s lymphoma: a systematic review and meta-analysis"],"prefix":"10.1186","volume":"21","author":[{"given":"Minyue","family":"Zhang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fei","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ling","family":"Peng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lijing","family":"Shen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peng","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beiwen","family":"Ni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jian","family":"Hou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6748-8798","authenticated-orcid":false,"given":"Honghui","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,10,9]]},"reference":[{"issue":"Suppl 8","key":"2230_CR1","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1289\/ehp.95103s8269","volume":"103","author":"G de The","year":"1995","unstructured":"de The G. Viruses and human cancers: challenges for preventive strategies. Environ Health Perspect. 1995;103(Suppl 8):269\u201373.","journal-title":"Environ Health Perspect"},{"issue":"3","key":"2230_CR2","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1056\/NEJMp038200","volume":"350","author":"J Parsonnet","year":"2004","unstructured":"Parsonnet J, Isaacson PG. Bacterial infection and MALT lymphoma. N Engl J Med. 2004;350(3):213\u20135.","journal-title":"N Engl J Med"},{"issue":"2","key":"2230_CR3","doi-asserted-by":"publisher","first-page":"153","DOI":"10.3322\/caac.21330","volume":"66","author":"M Raderer","year":"2016","unstructured":"Raderer M, Kiesewetter B, Ferreri AJ. Clinicopathologic characteristics and treatment of marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma). CA Cancer J Clin. 2016;66(2):153\u201371.","journal-title":"CA Cancer J Clin"},{"issue":"20","key":"2230_CR4","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","volume":"127","author":"SH Swerdlow","year":"2016","unstructured":"Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127(20):2375\u201390.","journal-title":"Blood"},{"issue":"4","key":"2230_CR5","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1053\/j.gastro.2005.12.039","volume":"130","author":"S Pal","year":"2006","unstructured":"Pal S, Sullivan DG, Kim S, Lai KK, Kae J, Cotler SJ, et al. Productive replication of hepatitis C virus in perihepatic lymph nodes in vivo: implications of HCV lymphotropism. Gastroenterology. 2006;130(4):1107\u201316.","journal-title":"Gastroenterology"},{"issue":"3","key":"2230_CR6","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1053\/j.gastro.2007.12.011","volume":"134","author":"TN Pham","year":"2008","unstructured":"Pham TN, King D, Macparland SA, McGrath JS, Reddy SB, Bursey FR, et al. Hepatitis C virus replicates in the same immune cell subsets in chronic hepatitis C and occult infection. Gastroenterology. 2008;134(3):812\u201322.","journal-title":"Gastroenterology"},{"issue":"6","key":"2230_CR7","doi-asserted-by":"publisher","first-page":"e0156384","DOI":"10.1371\/journal.pone.0156384","volume":"11","author":"D Canioni","year":"2016","unstructured":"Canioni D, Michot JM, Rabiega P, Molina TJ, Charlotte F, Lazure T, et al. In situ hepatitis C NS3 protein detection is associated with high grade features in hepatitis C-associated B-cell non-Hodgkin lymphomas. PLoS ONE. 2016;11(6):e0156384.","journal-title":"PLoS ONE"},{"issue":"11","key":"2230_CR8","doi-asserted-by":"publisher","first-page":"2078","DOI":"10.1158\/1055-9965.EPI-06-0308","volume":"15","author":"L Dal Maso","year":"2006","unstructured":"Dal Maso L, Franceschi S. Hepatitis C virus and risk of lymphoma and other lymphoid neoplasms: a meta-analysis of epidemiologic studies. Cancer Epidemiol Biomarkers Prev. 2006;15(11):2078\u201385.","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"6","key":"2230_CR9","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1200\/JCO.2005.01.5016","volume":"24","author":"C Besson","year":"2006","unstructured":"Besson C, Canioni D, Lepage E, Pol S, Morel P, Lederlin P, et al. Characteristics and outcome of diffuse large B-cell lymphoma in hepatitis C virus-positive patients in LNH 93 and LNH 98 Groupe d\u2019Etude des Lymphomes de l\u2019Adulte programs. J Clin Oncol. 2006;24(6):953\u201360.","journal-title":"J Clin Oncol"},{"issue":"2","key":"2230_CR10","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.leukres.2014.11.015","volume":"39","author":"TT Chen","year":"2015","unstructured":"Chen TT, Chiu CF, Yang TY, Lin CC, Sargeant AM, Yeh SP, et al. Hepatitis C infection is associated with hepatic toxicity but does not compromise the survival of patients with diffuse large B cell lymphoma treated with rituximab-based chemotherapy. Leuk Res. 2015;39(2):151\u20136.","journal-title":"Leuk Res"},{"issue":"3","key":"2230_CR11","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1016\/j.canep.2015.04.004","volume":"39","author":"YY Chen","year":"2015","unstructured":"Chen YY, Huang CE, Liang FW, Lu CH, Chen PT, Lee KD, et al. Prognostic impact of hepatitis C virus infection in patients with diffuse large B-cell lymphoma treated with immunochemotherapy in the context of a novel prognostic index. Cancer Epidemiol. 2015;39(3):382\u20137.","journal-title":"Cancer Epidemiol"},{"issue":"3","key":"2230_CR12","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1007\/s00277-016-2903-8","volume":"96","author":"I Dlouhy","year":"2017","unstructured":"Dlouhy I, Torrente MA, Lens S, Rovira J, Magnano L, Gine E, et al. Clinico-biological characteristics and outcome of hepatitis C virus-positive patients with diffuse large B-cell lymphoma treated with immunochemotherapy. Ann Hematol. 2017;96(3):405\u201310.","journal-title":"Ann Hematol"},{"issue":"8","key":"2230_CR13","doi-asserted-by":"publisher","first-page":"638","DOI":"10.2174\/1568009620666200511084731","volume":"20","author":"TA Elbedewy","year":"2020","unstructured":"Elbedewy TA, Elashtokhy HEA, Abd-Elsalam S, Suliman MA. Hepatitis C virus infection and treatment as independent prognostic factors in diffuse large B-cell lymphoma Egyptian patients. Curr Cancer Drug Targets. 2020;20(8):638\u201345.","journal-title":"Curr Cancer Drug Targets"},{"issue":"24","key":"2230_CR14","doi-asserted-by":"publisher","first-page":"5119","DOI":"10.1182\/blood-2010-06-289231","volume":"116","author":"D Ennishi","year":"2010","unstructured":"Ennishi D, Maeda Y, Niitsu N, Kojima M, Izutsu K, Takizawa J, et al. Hepatic toxicity and prognosis in hepatitis C virus-infected patients with diffuse large B-cell lymphoma treated with rituximab-containing chemotherapy regimens: a Japanese multicenter analysis. Blood. 2010;116(24):5119\u201325.","journal-title":"Blood"},{"issue":"3","key":"2230_CR15","doi-asserted-by":"publisher","first-page":"489","DOI":"10.3324\/haematol.2013.094318","volume":"99","author":"M Merli","year":"2014","unstructured":"Merli M, Visco C, Spina M, Luminari S, Ferretti VV, Gotti M, et al. Outcome prediction of diffuse large B-cell lymphomas associated with hepatitis C virus infection: a study on behalf of the Fondazione Italiana Linfomi. Haematologica. 2014;99(3):489\u201396.","journal-title":"Haematologica"},{"issue":"1","key":"2230_CR16","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1080\/10428190701732861","volume":"49","author":"BB Park","year":"2008","unstructured":"Park BB, Kim JS, Lee YY, Kang HJ, Ryoo BY, Kang JH, et al. Clinical characteristics and outcome for hepatitis C virus-positive diffuse large B-cell lymphoma. Leuk Lymphoma. 2008;49(1):88\u201394.","journal-title":"Leuk Lymphoma"},{"issue":"11","key":"2230_CR17","doi-asserted-by":"publisher","first-page":"2519","DOI":"10.1002\/ijc.30372","volume":"139","author":"J Hosry","year":"2016","unstructured":"Hosry J, Mahale P, Turturro F, Miranda RN, Economides MP, Granwehr BP, et al. Antiviral therapy improves overall survival in hepatitis C virus-infected patients who develop diffuse large B-cell lymphoma. Int J Cancer. 2016;139(11):2519\u201328.","journal-title":"Int J Cancer"},{"issue":"5","key":"2230_CR18","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1007\/s00277-019-03628-8","volume":"98","author":"J Shimono","year":"2019","unstructured":"Shimono J, Miyoshi H, Arakawa F, Yamada K, Sugio T, Miyawaki K, et al. Clinicopathological features of HCV-positive splenic diffuse large B cell lymphoma. Ann Hematol. 2019;98(5):1197\u2013207.","journal-title":"Ann Hematol"},{"issue":"7","key":"2230_CR19","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1093\/annonc\/mdu166","volume":"25","author":"L Arcaini","year":"2014","unstructured":"Arcaini L, Vallisa D, Rattotti S, Ferretti VV, Ferreri AJM, Bernuzzi P, et al. Antiviral treatment in patients with indolent B-cell lymphomas associated with HCV infection: a study of the Fondazione Italiana Linfomi. Ann Oncol. 2014;25(7):1404\u201310.","journal-title":"Ann Oncol"},{"issue":"3","key":"2230_CR20","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1002\/ajh.23889","volume":"90","author":"JM Michot","year":"2015","unstructured":"Michot JM, Canioni D, Driss H, Alric L, Cacoub P, Suarez F, et al. Antiviral therapy is associated with a better survival in patients with hepatitis C virus and B-cell non-Hodgkin lymphomas, ANRS HC-13 lympho-C study. Am J Hematol. 2015;90(3):197\u2013203.","journal-title":"Am J Hematol"},{"issue":"2","key":"2230_CR21","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1002\/hon.2575","volume":"37","author":"S Rattotti","year":"2019","unstructured":"Rattotti S, Ferretti VV, Rusconi C, Rossi A, Fogazzi S, Baldini L, et al. Lymphomas associated with chronic hepatitis C virus infection: A prospective multicenter cohort study from the Rete Ematologica Lombarda (REL) clinical network. Hematol Oncol. 2019;37(2):160\u20137.","journal-title":"Hematol Oncol"},{"issue":"7","key":"2230_CR22","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1179\/1607845413Y.0000000147","volume":"19","author":"AH Zaky","year":"2014","unstructured":"Zaky AH, Bakry R, El-sayed MI, Elwanis MA, Nabih O. Impact of treatment-related toxicity on outcome of HCV-positive diffuse large B-cell lymphoma in rituximab era. Hematology. 2014;19(7):412\u20136.","journal-title":"Hematology"},{"issue":"9","key":"2230_CR23","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1007\/s10654-010-9491-z","volume":"25","author":"A Stang","year":"2010","unstructured":"Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010;25(9):603\u20135.","journal-title":"Eur J Epidemiol"},{"key":"2230_CR24","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/1745-6215-8-16","volume":"8","author":"JF Tierney","year":"2007","unstructured":"Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials. 2007;8:16.","journal-title":"Trials"},{"issue":"12","key":"2230_CR25","doi-asserted-by":"publisher","first-page":"1564","DOI":"10.1016\/j.leukres.2011.07.018","volume":"35","author":"MY Zhang","year":"2011","unstructured":"Zhang MY, Chen FY, Zhong H. Meta-analysis of human leukocyte antigen genetic polymorphisms and susceptibility to chronic myelogenous leukemia in Chinese population. Leuk Res. 2011;35(12):1564\u201370.","journal-title":"Leuk Res"},{"issue":"2","key":"2230_CR26","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.neures.2010.06.011","volume":"68","author":"MY Zhang","year":"2010","unstructured":"Zhang MY, Miao L, Li YS, Hu GY. Meta-analysis of the methylenetetrahydrofolate reductase C677T polymorphism and susceptibility to Alzheimer\u2019s disease. Neurosci Res. 2010;68(2):142\u201350.","journal-title":"Neurosci Res"},{"issue":"21","key":"2230_CR27","doi-asserted-by":"publisher","first-page":"30642","DOI":"10.18632\/oncotarget.8907","volume":"7","author":"MY Zhang","year":"2016","unstructured":"Zhang MY, Zhu GQ, Shi KQ, Zheng JN, Cheng Z, Zou ZL, et al. Systematic review with network meta-analysis: Comparative efficacy of oral nucleos(t)ide analogues for the prevention of chemotherapy-induced hepatitis B virus reactivation. Oncotarget. 2016;7(21):30642\u201358.","journal-title":"Oncotarget"},{"issue":"5","key":"2230_CR28","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1080\/14787210.2017.1309291","volume":"15","author":"MY Zhang","year":"2017","unstructured":"Zhang MY, Zhu GQ, Zheng JN, Cheng Z, Van Poucke S, Shi KQ, et al. Nucleos(t)ide analogues for preventing HBV reactivation in immunosuppressed patients with hematological malignancies: a network meta-analysis. Expert Rev Anti Infect Ther. 2017;15(5):503\u201313.","journal-title":"Expert Rev Anti Infect Ther"},{"issue":"3","key":"2230_CR29","doi-asserted-by":"publisher","first-page":"835","DOI":"10.3892\/or.2012.1883","volume":"28","author":"H Nishikawa","year":"2012","unstructured":"Nishikawa H, Tsudo M, Osaki Y. Clinical outcome in diffuse large B-cell lymphoma with hepatitis C virus infection in the rituximab era: a single center experience. Oncol Rep. 2012;28(3):835\u201340.","journal-title":"Oncol Rep"},{"issue":"2","key":"2230_CR30","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1093\/annonc\/mdl388","volume":"18","author":"L Arcaini","year":"2007","unstructured":"Arcaini L, Burcheri S, Rossi A, Paulli M, Bruno R, Passamonti F, et al. Prevalence of HCV infection in nongastric marginal zone B-cell lymphoma of MALT. Ann Oncol. 2007;18(2):346\u201350.","journal-title":"Ann Oncol"},{"issue":"12","key":"2230_CR31","doi-asserted-by":"publisher","first-page":"4643","DOI":"10.1182\/blood-2005-11-4659","volume":"107","author":"L Arcaini","year":"2006","unstructured":"Arcaini L, Lazzarino M, Colombo N, Burcheri S, Boveri E, Paulli M, et al. Splenic marginal zone lymphoma: a prognostic model for clinical use. Blood. 2006;107(12):4643\u20139.","journal-title":"Blood"},{"issue":"3","key":"2230_CR32","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1002\/hon.2731","volume":"38","author":"J Hosry","year":"2020","unstructured":"Hosry J, Miranda RN, Samaniego F, Angelidakis G, Torres HA. Clinicopathologic characteristics of follicular lymphoma in hepatitis C virus-infected patients. Hematol Oncol. 2020;38(3):301\u20138.","journal-title":"Hematol Oncol"},{"issue":"4","key":"2230_CR33","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1002\/hon.2751","volume":"38","author":"E Nesterova","year":"2020","unstructured":"Nesterova E, Tanaschuk E, Abdurakhmanov D, Gemdzhian E, Kravchenko S, Mangasarova Y, et al. Safe and effective treatment of follicular lymphoma in patients with HCV-infection. Hematol Oncol. 2020;38(4):604\u20136.","journal-title":"Hematol Oncol"},{"issue":"2","key":"2230_CR34","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1182\/blood.V90.2.776.776_776_782","volume":"90","author":"S De Vita","year":"1997","unstructured":"De Vita S, Sacco C, Sansonno D, Gloghini A, Dammacco F, Crovatto M, et al. Characterization of overt B-cell lymphomas in patients with hepatitis C virus infection. Blood. 1997;90(2):776\u201382.","journal-title":"Blood"},{"issue":"5","key":"2230_CR35","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1023\/A:1008255830453","volume":"9","author":"M Luppi","year":"1998","unstructured":"Luppi M, Longo G, Ferrari MG, Barozzi P, Marasca R, Morselli M, et al. Clinico-pathological characterization of hepatitis C virus-related B-cell non-Hodgkin\u2019s lymphomas without symptomatic cryoglobulinemia. Ann Oncol. 1998;9(5):495\u20138.","journal-title":"Ann Oncol"},{"issue":"4","key":"2230_CR36","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1016\/j.jhep.2008.06.025","volume":"49","author":"V La Mura","year":"2008","unstructured":"La Mura V, De Renzo A, Perna F, D\u2019Agostino D, Masarone M, Romano M, et al. Antiviral therapy after complete response to chemotherapy could be efficacious in HCV-positive non-Hodgkin\u2019s lymphoma. J Hepatol. 2008;49(4):557\u201363.","journal-title":"J Hepatol"},{"issue":"10","key":"2230_CR37","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1001\/archophthalmol.2010.233","volume":"128","author":"D Strianese","year":"2010","unstructured":"Strianese D, Tranfa F, Finelli M, De Renzo A, Staibano S, Schiemer R, et al. Hepatitis C virus infection in ocular adnexal lymphomas. Arch Ophthalmol. 2010;128(10):1295\u20139.","journal-title":"Arch Ophthalmol"},{"issue":"6","key":"2230_CR38","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1080\/10428194.2016.1236376","volume":"58","author":"K Tajima","year":"2017","unstructured":"Tajima K, Takahashi N, Ishizawa K, Murai K, Akagi T, Noji H, et al. Clinicopathological characteristics of malignant lymphoma in patients with hepatitis C virus infection in the Tohoku district in Eastern Japan. Leuk Lymphoma. 2017;58(6):1509\u201311.","journal-title":"Leuk Lymphoma"},{"issue":"5","key":"2230_CR39","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1016\/S0002-9343(99)00069-8","volume":"106","author":"D Vallisa","year":"1999","unstructured":"Vallisa D, Bert\u00e8 R, Rocca A, Civardi G, Giangregorio F, Ferrari B, et al. Association between hepatitis C virus and non-Hodgkin\u2019s lymphoma, and effects of viral infection on histologic subtype and clinical course. Am J Med. 1999;106(5):556\u201360.","journal-title":"Am J Med"},{"issue":"1","key":"2230_CR40","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1002\/hep.29364","volume":"67","author":"M Persico","year":"2018","unstructured":"Persico M, Aglitti A, Caruso R, De Renzo A, Selleri C, Califano C, et al. Efficacy and safety of new direct antiviral agents in hepatitis C virus-infected patients with diffuse large B-cell non-Hodgkin\u2019s lymphoma. Hepatology. 2018;67(1):48\u201355.","journal-title":"Hepatology"},{"issue":"11","key":"2230_CR41","doi-asserted-by":"publisher","first-page":"1903","DOI":"10.1007\/s00277-014-2138-5","volume":"93","author":"MA Salah-Eldin","year":"2014","unstructured":"Salah-Eldin MA, Ebrahim MA, El-Sadda W. Clinical outcome of HCV-positive patients with diffuse large B-cell lymphoma treated with rituximab-based chemotherapy. Ann Hematol. 2014;93(11):1903\u201311.","journal-title":"Ann Hematol"},{"key":"2230_CR42","volume-title":"Global Hepatitis Report 2017","author":"World Health Organization","year":"2017","unstructured":"World Health Organization. Global Hepatitis Report 2017. Geneva: World Health Organization; 2017."},{"issue":"6","key":"2230_CR43","doi-asserted-by":"publisher","first-page":"1792","DOI":"10.1182\/blood-2010-06-275818","volume":"117","author":"F Marcucci","year":"2011","unstructured":"Marcucci F, Mele A. Hepatitis viruses and non-Hodgkin lymphoma: epidemiology, mechanisms of tumorigenesis, and therapeutic opportunities. Blood. 2011;117(6):1792\u20138.","journal-title":"Blood"},{"issue":"7","key":"2230_CR44","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1080\/1042819031000076972","volume":"44","author":"WK Weng","year":"2003","unstructured":"Weng WK, Levy S. Hepatitis C virus (HCV) and lymphomagenesis. Leuk Lymphoma. 2003;44(7):1113\u201320.","journal-title":"Leuk Lymphoma"},{"issue":"40","key":"2230_CR45","doi-asserted-by":"publisher","first-page":"5580","DOI":"10.1038\/sj.onc.1204640","volume":"20","author":"R K\u00fcppers","year":"2001","unstructured":"K\u00fcppers R, Dalla-Favera R. Mechanisms of chromosomal translocations in B cell lymphomas. Oncogene. 2001;20(40):5580\u201394.","journal-title":"Oncogene"},{"issue":"3","key":"2230_CR46","doi-asserted-by":"publisher","first-page":"327","DOI":"10.4254\/wjh.v7.i3.327","volume":"7","author":"C Ferri","year":"2015","unstructured":"Ferri C, Sebastiani M, Giuggioli D, Colaci M, Fallahi P, Piluso A, et al. Hepatitis C virus syndrome: a constellation of organ- and non-organ specific autoimmune disorders, B-cell non-Hodgkin\u2019s lymphoma, and cancer. World J Hepatol. 2015;7(3):327\u201343.","journal-title":"World J Hepatol"},{"key":"2230_CR47","doi-asserted-by":"publisher","first-page":"807351","DOI":"10.1155\/2012\/807351","volume":"2012","author":"F Forghieri","year":"2012","unstructured":"Forghieri F, Luppi M, Barozzi P, Maffei R, Potenza L, Narni F, et al. Pathogenetic mechanisms of hepatitis C virus-induced B-cell lymphomagenesis. Clin Dev Immunol. 2012;2012:807351.","journal-title":"Clin Dev Immunol"},{"issue":"1","key":"2230_CR48","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.jhep.2013.03.018","volume":"59","author":"J Peveling-Oberhag","year":"2013","unstructured":"Peveling-Oberhag J, Arcaini L, Hansmann ML, Zeuzem S. Hepatitis C-associated B-cell non-Hodgkin lymphomas. Epidemiology, molecular signature and clinical management. J Hepatol. 2013;59(1):169\u201377.","journal-title":"J Hepatol"},{"issue":"7","key":"2230_CR49","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1111\/jvh.12518","volume":"23","author":"J Peveling-Oberhag","year":"2016","unstructured":"Peveling-Oberhag J, Arcaini L, Bankov K, Zeuzem S, Herrmann E. The anti-lymphoma activity of antiviral therapy in HCV-associated B-cell non-Hodgkin lymphomas: a meta-analysis. J Viral Hepat. 2016;23(7):536\u201344.","journal-title":"J Viral Hepat"}],"container-title":["Cancer Cell International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12935-021-02230-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12935-021-02230-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12935-021-02230-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,10]],"date-time":"2021-10-10T20:58:11Z","timestamp":1633899491000},"score":1,"resource":{"primary":{"URL":"https:\/\/cancerci.biomedcentral.com\/articles\/10.1186\/s12935-021-02230-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,9]]},"references-count":49,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["2230"],"URL":"https:\/\/doi.org\/10.1186\/s12935-021-02230-1","relation":{},"ISSN":["1475-2867"],"issn-type":[{"type":"electronic","value":"1475-2867"}],"subject":[],"published":{"date-parts":[[2021,10,9]]},"assertion":[{"value":"12 May 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 September 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 October 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"524"}}